Rapidly proliferating tumor and normal cells

Rapidly proliferating tumor and normal cells represent a biological state rather than a specific molecular target. This phenotype is characterized by high rates of DNA synthesis and frequent entry into mitosis, making such cells highly susceptible to traditional cytotoxic chemotherapy (National Cancer Institute, 2023). While these therapies are designed to kill cancer cells, they also affect healthy tissues with high turnover rates, such as the hematopoietic system, the gastrointestinal lining, and hair follicles (StatPearls, 2023). This lack of specificity leads to the characteristic side effects of chemotherapy, including bone marrow suppression and hair loss (American Cancer Society, 2024). Modern oncology often seeks to move beyond this broad phenotype toward more specific molecular targets to improve the therapeutic index and reduce systemic toxicity. Biomarkers such as Ki-67 and PCNA are commonly used to quantify this proliferative state in clinical samples (PubMed, 2022).

Other names

Proliferating cellsMitotically active cellsDividing cellsHyperproliferative cells

Cytotoxic agents disrupt DNA synthesis, cause DNA damage, or inhibit mitotic spindle formation, leading to cell cycle arrest and apoptosis in cells undergoing active division (StatPearls, 2023).